Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.89, $0.20 better than the analyst estimate of $0.69. Revenue for the quarter came in at $178 million versus the consensus estimate of $173.52 million.

GUIDANCE:

Pacira Pharma sees FY2024 revenue of $680-705 million, versus the consensus of $695.4 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.